Skip to main content
icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

12% chance
Polymarket

$79,467 Vol.

12% chance
Polymarket

$79,467 Vol.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**The absence of Phase 3 clinical trials for any hantavirus vaccine candidate drives the strong 88.5% market-implied probability for "No" by year-end, reflecting trader consensus on regulatory timelines amid CDC and WHO confirmation of no licensed vaccines worldwide.** A recent Andes virus outbreak on cruise ship MV Hondius—eight cases (six confirmed), three deaths as of May 8—has spurred preclinical efforts like Moderna's mRNA platform and University of Bath's glycoprotein vaccine nearing Phase 1, but hantavirus pulmonary syndrome's rarity (under 1,000 global cases yearly) hampers large efficacy studies. Historical Phase 1/2a trials for Andes and Hantaan DNA vaccines stalled years ago without advancement. Upcoming forecast updates from WHO and potential Phase 1 initiations offer no path to approval in the next seven months absent Warp Speed-scale intervention.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$79,467
Data de Término
31 dez 2026
Mercado Aberto
May 4, 2026, 10:39 AM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**The absence of Phase 3 clinical trials for any hantavirus vaccine candidate drives the strong 88.5% market-implied probability for "No" by year-end, reflecting trader consensus on regulatory timelines amid CDC and WHO confirmation of no licensed vaccines worldwide.** A recent Andes virus outbreak on cruise ship MV Hondius—eight cases (six confirmed), three deaths as of May 8—has spurred preclinical efforts like Moderna's mRNA platform and University of Bath's glycoprotein vaccine nearing Phase 1, but hantavirus pulmonary syndrome's rarity (under 1,000 global cases yearly) hampers large efficacy studies. Historical Phase 1/2a trials for Andes and Hantaan DNA vaccines stalled years ago without advancement. Upcoming forecast updates from WHO and potential Phase 1 initiations offer no path to approval in the next seven months absent Warp Speed-scale intervention.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$79,467
Data de Término
31 dez 2026
Mercado Aberto
May 4, 2026, 10:39 AM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.

Cuidado com os links externos.

Frequently Asked Questions

"Hantavirus vaccine in 2026? " is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 12% for "Yes." For example, if "Yes" is priced at 12¢, the market collectively assigns a 12% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "Hantavirus vaccine in 2026? " has generated $79.5K in total trading volume since the market launched on May 4, 2026. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "Hantavirus vaccine in 2026? ," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "Hantavirus vaccine in 2026? " is 12% for "Yes." This means the Polymarket crowd currently believes there is a 12% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "Hantavirus vaccine in 2026? " define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.